Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Hester Biosciences has informed that Board of Directors, in their Meeting held today, have approved, Unaudited Standalone Financial Results for the quarter and half year ended on 30 September, 2018, declared 2nd interim dividend of 20% that is INR 2.00 per equity share on the face value of INR 10 per share. The company has already paid 1st Interim Dividend of INR 2.00 per equity shares, and revision in remuneration of Rajiv Gandhi, CEO & Managing Director of the Company for the current tenure ending on 31 March 2020, subject to approval of Members.
The above information is a part of company’s filings submitted to BSE.
